|
|
Blood, 15 April 2004, Vol. 103, No. 8, pp. 3158-3166.
Prepublished online as a Blood First Edition Paper on December 11, 2003; DOI 10.1182/blood-2003-08-2873.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic antimultiple myeloma (MM) activity and overcome bortezomib resistance
Dharminder Chauhan,
Guilan Li,
Klaus Podar,
Teru Hideshima,
Reshma Shringarpure,
Laurence Catley,
Constantine Mitsiades,
Nikhil Munshi,
Yu Tzu Tai,
Nanjoo Suh,
Gordon W. Gribble,
Tadashi Honda,
Robert Schlossman,
Paul Richardson,
Michael B. Sporn, and
Kenneth C. Anderson
From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Chemistry, Dartmouth College, Hanover, NH; and Department of Pharmacology, Dartmouth Medical School, Hanover, NH.
The synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO) induces apoptosis in leukemic cells. Here we show that CDDO and its new derivative CDDO-imidazolide (CDDO-Im) trigger apoptosis in multiple myeloma (MM) cells resistant to conventional therapies including melphalan (LR-5), doxorubicin (Dox-40), and dexamethasone (MM.1R, U266, RPMI 8226) without affecting the viability of normal cells. CDDO-IM also triggers apoptosis in bone marrow stromal cells (BMSCs) and decreases interleukin-6 (IL-6) secretion induced by MM cell adhesion to BMSCs. Moreover, CDDO-Iminduced apoptosis in MM cells is not blocked by IL-6 or insulin growth factor-1 (IGF-1). Importantly, CDDO-Im and bortezomib/proteasome inhibitor PS-341 trigger synergistic apoptosis in MM cells associated with loss of mitochondrial membrane potential, superoxide generation, release of mitochondrial proteinscytochrome c/second mitochondria-derived activator of caspases (cyctochrome c/Smac), and activation of caspase-8, -9, and -3. Conversely, the pancaspase inhibitor Z-VAD-fmk abrogates the CDDO-Im + bortezomibinduced apoptosis. Low doses of CDDO-Im and bortezomib overcome the cytoprotective effects of antiapoptotic proteins Bcl2 and heat shock protein-27 (Hsp27) as well as nuclear factorkappa B (NF- B)mediated growth/survival and drug resistance. Finally, combining CDDO-Im and bortezomib induces apoptosis even in bortezomib-resistant MM patient cells. Together, these findings provide the framework for clinical evaluation of CDDO-Im, either alone or in combination with bortezomib, to overcome drug resistance and improve patient outcome in MM. (Blood. 2004;103: 3158-3166)

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Ahmad, D. Raina, C. Meyer, and D. Kufe
Triterpenoid CDDO-Methyl Ester Inhibits the Janus-Activated Kinase-1 (JAK1)->Signal Transducer and Activator of Transcription-3 (STAT3) Pathway by Direct Inhibition of JAK1 and STAT3
Cancer Res.,
April 15, 2008;
68(8):
2920 - 2926.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Zoubeidi, A. Zardan, E. Beraldi, L. Fazli, R. Sowery, P. Rennie, C. Nelson, and M. Gleave
Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity
Cancer Res.,
November 1, 2007;
67(21):
10455 - 10465.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Yang, X. Zhang, J. Wang, J. Qian, L. Zhang, M. Wang, L. W. Kwak, and Q. Yi
Anti {beta}2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts
Blood,
October 15, 2007;
110(8):
3028 - 3035.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bhutani, A. K. Pathak, A. S. Nair, A. B. Kunnumakkara, S. Guha, G. Sethi, and B. B. Aggarwal
Capsaicin Is a Novel Blocker of Constitutive and Interleukin-6-Inducible STAT3 Activation
Clin. Cancer Res.,
May 15, 2007;
13(10):
3024 - 3032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Roman-Gomez, L. Cordeu, X. Agirre, A. Jimenez-Velasco, E. San Jose-Eneriz, L. Garate, M. J. Calasanz, A. Heiniger, A. Torres, and F. Prosper
Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia
Blood,
April 15, 2007;
109(8):
3462 - 3469.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-P. Armand, A. K. Burnett, J. Drach, J.-L. Harousseau, B. Lowenberg, and J. San Miguel
The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib
Oncologist,
March 1, 2007;
12(3):
281 - 290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. S. Brookes, K. Morse, D. Ray, A. Tompkins, S. M. Young, S. Hilchey, S. Salim, M. Konopleva, M. Andreeff, R. Phipps, et al.
The Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid and Its Derivatives Elicit Human Lymphoid Cell Apoptosis through a Novel Pathway Involving the Unregulated Mitochondrial Permeability Transition Pore
Cancer Res.,
February 15, 2007;
67(4):
1793 - 1802.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Yore, K. T. Liby, T. Honda, G. W. Gribble, and M. B. Sporn
The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-{kappa}B activation through direct inhibition of I{kappa}B kinase {beta}
Mol. Cancer Ther.,
December 1, 2006;
5(12):
3232 - 3239.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Liby, N. Voong, C. R. Williams, R. Risingsong, D. B. Royce, T. Honda, G. W. Gribble, M. B. Sporn, and J. J. Letterio
The Synthetic Triterpenoid CDDO-Imidazolide Suppresses STAT Phosphorylation and Induces Apoptosis in Myeloma and Lung Cancer Cells.
Clin. Cancer Res.,
July 15, 2006;
12(14):
4288 - 4293.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Konopleva, W. Zhang, Y.-X. Shi, T. McQueen, T. Tsao, M. Abdelrahim, M. F. Munsell, M. Johansen, D. Yu, T. Madden, et al.
Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells.
Mol. Cancer Ther.,
February 1, 2006;
5(2):
317 - 328.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Samudio, M. Konopleva, N. Hail Jr., Y.-X. Shi, T. McQueen, T. Hsu, R. Evans, T. Honda, G. W. Gribble, M. Sporn, et al.
2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) Directly Targets Mitochondrial Glutathione to Induce Apoptosis in Pancreatic Cancer
J. Biol. Chem.,
October 28, 2005;
280(43):
36273 - 36282.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson
Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6345 - 6350.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Liby, T. Hock, M. M. Yore, N. Suh, A. E. Place, R. Risingsong, C. R. Williams, D. B. Royce, T. Honda, Y. Honda, et al.
The Synthetic Triterpenoids, CDDO and CDDO-Imidazolide, Are Potent Inducers of Heme Oxygenase-1 and Nrf2/ARE Signaling
Cancer Res.,
June 1, 2005;
65(11):
4789 - 4798.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Nencioni, L. Wille, G. Dal Bello, D. Boy, G. Cirmena, S. Wesselborg, C. Belka, P. Brossart, F. Patrone, and A. Ballestrero
Cooperative Cytotoxicity of Proteasome Inhibitors and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Chemoresistant Bcl-2-Overexpressing Cells
Clin. Cancer Res.,
June 1, 2005;
11(11):
4259 - 4265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Chauhan, T. Hideshima, C. Mitsiades, P. Richardson, and K. C. Anderson
Proteasome inhibitor therapy in multiple myeloma
Mol. Cancer Ther.,
April 1, 2005;
4(4):
686 - 692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gaikwad, A. Poblenz, V. Haridas, C. Zhang, M. Duvic, and J. Gutterman
Triterpenoid Electrophiles (Avicins) Suppress Heat Shock Protein-70 and X-Linked Inhibitor of Apoptosis Proteins in Malignant Cells by Activation of Ubiquitin Machinery: Implications for Proapoptotic Activity
Clin. Cancer Res.,
March 1, 2005;
11(5):
1953 - 1962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Eminel, A. Klettner, L. Roemer, T. Herdegen, and V. Waetzig
JNK2 Translocates to the Mitochondria and Mediates Cytochrome c Release in PC12 Cells in Response to 6-Hydroxydopamine
J. Biol. Chem.,
December 31, 2004;
279(53):
55385 - 55392.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Chauhan, G. Li, K. Podar, T. Hideshima, C. Mitsiades, R. Schlossman, N. Munshi, P. Richardson, F. E. Cotter, and K. C. Anderson
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
Blood,
October 15, 2004;
104(8):
2458 - 2466.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |